Physician profile
Dawn Brunner
NPI 1063643187
$781.21
in general payments reported to CMS, 2019-2025
14 companies · $13.51 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $193 · 2021: $389 · 2022: $52.03 · 2023: $13.34 · 2025: $13.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $283.91 | 2020-2022 | |
| Abbvie INC. | $79.55 | 2021 | |
| Allergan, INC. | $71.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.18 | 2019-2021 | |
| Novo Nordisk INC | $61.49 | 2020-2021 | |
| Amarin Pharma, INC. | $36.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.26 | 2019-2020 | |
| Amgen INC. | $28.70 | 2022-2023 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $25.15 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.26 | 2021 | |
| Merck Sharp & Dohme LLC | $19.85 | 2021 | |
| Gilead Sciences, INC. | $17.95 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2019 | |
| Exact Sciences Corporation | $13.51 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Brunner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.